RCKT ROCKET PHARMACEUTICALS, INC.companySEC Filings & Insider Trading Activity 2026
Latest ROCKET PHARMACEUTICALS, INC. (RCKT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 28, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ROCKET PHARMACEUTICALS, INC. (RCKT) (SEC CIK 1281895), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.02: Termination of a Material Definitive Agreement
- • Rocket Pharma terminated its prior ATM agreement with Cowen and Company (TD Securities affiliate), originally dated Feb 28, 2022
- • Termination triggered by entry into a new Sales Agreement, signaling a change in ATM program counterparty or structure
Item 1.01: Entry into a Material Definitive Agreement
- • ATM offering up to $100M in common stock via Cantor Fitzgerald, filed March 10, 2026 under existing S-3 shelf registration
- • Sales agent commission up to 3.0% of gross proceeds — maximum dilution cost ~$3M if fully drawn
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ROCKET PHARMACEUTICALS, INC. (RCKT) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$224.3M | -$259.7M | -$273.2M | -$231.7M |
| Net Income | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| Balance Sheet | ||||
| Total Assets | $551.8M | $566.3M | $527.7M | $330.4M |
| Equity | $489.7M | $492.6M | $463.2M | $277.2M |
| ROE | -45.3% | -49.9% | -55.9% | -80.5% |
Source: XBRL financial data from ROCKET PHARMACEUTICALS, INC. (RCKT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 28, 2026 | — | — | — |
8-K | Mar 27, 2026 | — | — | — |
8-K | Mar 10, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 27, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 5, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 4, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 5, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 9, 2021 | Jun 30, 2021 | — | |
10-Q | May 10, 2021 | Mar 31, 2021 | — | |
10-K | Mar 1, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest RCKT SEC filings in 2026?
ROCKET PHARMACEUTICALS, INC. (RCKT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did RCKT file its most recent 10-K annual report?
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view RCKT 10-Q quarterly reports?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every RCKT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has RCKT filed recently?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find RCKT insider trading activity (Form 4)?
SignalX aggregates every RCKT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does RCKT file with the SEC?
ROCKET PHARMACEUTICALS, INC. (RCKT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RCKT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ROCKET PHARMACEUTICALS, INC. (RCKT).
What is RCKT's SEC CIK number?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s SEC CIK (Central Index Key) number is 1281895. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1281895 to look up all RCKT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find RCKT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ROCKET PHARMACEUTICALS, INC. (RCKT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ROCKET PHARMACEUTICALS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 49+ filings.